利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.021 秒)

    Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
    2.
    发明授权
    Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor 失效
    抑制通过半胱氨酸或丝氨酸蛋白酶抑制剂的光动力学治疗诱导凋亡的方法

    公开(公告)号：US06180402B2

    公开(公告)日：2001-01-30

    申请号：US08754491

    申请日：1996-11-20

    申请人： David J. Granville ,  Julia G. Levy ,  David W. C. Hunt

    发明人： David J. Granville ,  Julia G. Levy ,  David W. C. Hunt

    IPC分类号： C12N500

    CPC分类号： A61K31/16 ,  A61K31/198 ,  A61K31/37

    摘要： A composition and method for inhibiting apoptosis, or decreasing the rate or extent of apoptosis, in target cells. The method comprises the step of the step of contacting the target cells with an apoptosis-regulating amount of at least one cysteine or serine protease inhibitor that: a. inhibits the conversion of the pro-enzyme form of CPP32 to its enzymatically-active form; b. blocks the proteolytic action of activated CPP32 against its cellular substrates; or c. both. The method is particularly applicable to ameliorating the side effects of, or enhancing the selectivity, of photodynamic therapy.

    摘要翻译： 用于抑制细胞凋亡或降低细胞凋亡的速度或程度的组合物和方法。 该方法包括以下步骤：使靶细胞与凋亡调节量的至少一种半胱氨酸或丝氨酸蛋白酶抑制剂接触的步骤：a。 抑制原酶形式的CPP32转化为其酶活性形式; b。 阻断活化CPP32对其细胞底物的蛋白水解作用; 兽人 这两种方法特别适用于改善光动力疗法的副作用或提高选择性。

    Wavelength-specific cytotoxic agents
    4.
    发明授权
    Wavelength-specific cytotoxic agents 失效
    波长特异性细胞毒性剂

    公开(公告)号：US5283255A

    公开(公告)日：1994-02-01

    申请号：US943895

    申请日：1992-09-11

    申请人： Julia G. Levy ,  David Dolphin ,  Jack J. Chow ,  Ethan Sternberg

    发明人： Julia G. Levy ,  David Dolphin ,  Jack J. Chow ,  Ethan Sternberg

    IPC分类号： A61K41/00 ,  A61K49/00 ,  A61K51/04 ,  A61K51/10 ,  C07D487/22 ,  C07D519/00 ,  A61K31/40

    CPC分类号： A61K41/0071 ,  A61K49/0036 ,  A61K51/0485 ,  A61K51/1093 ,  C07D487/22 ,  C07D519/00 ,  A61K2121/00

    摘要： A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.

    摘要翻译： 具有吸收最大值在670-780纳米范围内的一组氢 - 单苯并卟啉“绿色卟啉”（Gp）可用于治疗在光存在下经受血卟啉衍生物（HPD）治疗的病症或病症，或治疗 病毒，细胞和组织通常会破坏不想要的靶。 使用本发明的Gp允许用于治疗的照射使用除了被血液吸收的波长以外的波长。 本发明的Gp还可以与受体特异性配体或特异性免疫球蛋白或其片段缀合以靶向用于放射治疗的特定组织或细胞。 使用这些材料允许使用较低水平的药物，从而防止可能破坏正常组织的副反应。

    Benzoporphyrin derivatives for photodynamic therapy
    5.
    发明授权
    Benzoporphyrin derivatives for photodynamic therapy 失效
    苯并卟啉衍生物用于光动力疗法

    公开(公告)号：US5214036A

    公开(公告)日：1993-05-25

    申请号：US491674

    申请日：1990-03-08

    申请人： Beth A. Allison ,  Anna M. Richter ,  P. Haydn Pritchard ,  Julia G. Levy

    发明人： Beth A. Allison ,  Anna M. Richter ,  P. Haydn Pritchard ,  Julia G. Levy

    IPC分类号： A61K31/40 ,  A61K41/00

    CPC分类号： A61K41/0071 ,  A61K31/40

    摘要： Green porphyrins (Gp), compounds important in photodynamic therapy, have been associated with lipocomplexes to reduce the required amount of photosensitizer through higher effective absorption and increased specificity. BPDs, especially in conjunction with the HDL fraction of plasma lipoproteins, has been shown to be particularly effective in this context. Pharmaceutical compositions in which these combinations are the active ingredients for use in diagnosis and treatment of tumors are also disclosed.

    摘要翻译： 绿光卟啉（Gp）是光动力学治疗中重要的化合物，与脂质复合物有关，通过更高的有效吸收和增加的特异性降低所需量的光敏剂。 BPD，特别是与血浆脂蛋白的HDL分数结合已被证明在这方面特别有效。 还公开了这些组合是用于诊断和治疗肿瘤的活性成分的药物组合物。

    Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
    6.
    发明授权
    Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents 失效
    水 - 单苯并卟啉波长特异性细胞毒素

    公开(公告)号：US4920143A

    公开(公告)日：1990-04-24

    申请号：US221161

    申请日：1988-07-19

    申请人： Julia G. Levy ,  David Dolphin ,  Jack K. Chow ,  Ethan Sternberg

    发明人： Julia G. Levy ,  David Dolphin ,  Jack K. Chow ,  Ethan Sternberg

    IPC分类号： A61K41/00 ,  A61K49/00 ,  A61K51/04 ,  A61K51/10 ,  C07D487/22 ,  C07D519/00

    CPC分类号： A61K51/0485 ,  A61K41/0071 ,  A61K49/0036 ,  A61K49/0058 ,  A61K51/1093 ,  C07D487/22 ,  C07D519/00 ,  A61K2121/00

    摘要： A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.

    摘要翻译： 具有吸收最大值在670-780纳米范围内的一组氢 - 单苯并卟啉“绿色卟啉”（Gp）可用于治疗在光存在下经受血卟啉衍生物（HPD）治疗的病症或病症，或治疗 病毒，细胞和组织通常会破坏不想要的靶。 本发明的Gp的使用允许照射使用除血液吸收的波长以外的波长。 本发明的Gp还可以与受体特异性配体或特异性免疫球蛋白或其片段缀合以靶向用于放射治疗的特定组织或细胞。 使用这些材料允许使用较低水平的药物，从而防止可能破坏正常组织的副反应。

    Method for reducing or preventing PDT related inflammation
    8.
    发明授权
    Method for reducing or preventing PDT related inflammation 有权
    降低或预防PDT相关炎症的方法

    公开(公告)号：US08106038B2

    公开(公告)日：2012-01-31

    申请号：US10081010

    申请日：2002-02-15

    申请人： Philippe Maria Clotaire Margaron ,  Anna M. Richter ,  Julia G. Levy

    发明人： Philippe Maria Clotaire Margaron ,  Anna M. Richter ,  Julia G. Levy

    IPC分类号： A61K31/55

    CPC分类号： A61K41/0057 ,  A61K41/0071 ,  Y10S514/912

    摘要： This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.

    摘要翻译： 本发明一般涉及药物治疗领域和光动力疗法（“PDT”）的使用。 特别地，本发明提供了减少或预防由正常剂量光动力治疗（PDT）引起的炎症影响的方法，该方法包括将已经用正常剂量PDT治疗的受试者中的靶组织暴露于具有 由在所述正常剂量PDT处理中使用的光敏剂吸收的波长足以减少或防止由所述正常剂量PDT处理引起的炎症的影响的时间。 该方法特别可用于减少或预防由正常剂量PDT治疗眼组织引起的炎症的作用。